Stringer et al. (2016) demonstrated that low NFIB mRNA expression was associated with increased astrocytoma grade and mesenchymal subtype of glioblastoma. Glioblastoma multiforme (GBM) patients with higher NFIB expression survived significantly longer than patients with lower NFIB expression. In another study, NFIX DNA hypermethylation was reportedly associated with significantly decreased NFIX expression and was related to shorter OS and RFS in patients with lung adenocarcinoma (Ge et al., 2018). The gene discussed is NFIB; the disease is astrocytoma (excluding glioblastoma).